The first “theragnostic model”, that of radioiodine, was first applied both in diagnosis and therapy in the 1940s. Since then, many other theragnostic models have been introduced into clinical practice. To bring about the closest pharmacokinetic connection, the radiocompound used for diagnosis and therapy should be the same, although at present this is rarely applicable. Today, a widely applied and effective model is also the “DOTA-Ga-68/Lu-177”, used with success in neuroendocrine tumors (NET). In this paper, we analyze the necessary steps from the in vitro evaluation of a target to the choice of radionuclide and chelate for therapy up to in vivo transition and clinical application of most employed radiocompounds used for theragnostic purposes. Possible future applications and strategies of theragnostic models are also highlighted.
CITATION STYLE
Di Stasio, G. D., Buonomano, P., Travaini, L. L., Grana, C. M., & Mansi, L. (2021, July 2). From the magic bullet to theragnostics: Certitudes and hypotheses, trying to optimize the somatostatin model. Cancers. MDPI AG. https://doi.org/10.3390/cancers13143474
Mendeley helps you to discover research relevant for your work.